InvestmentMay 8, 2026, 04:08 PM
Entera Bio Secures Investment, Advances Oral Peptide Pipeline
AI Summary
Entera Bio Ltd. reported its first-quarter 2026 financial results, including a net loss of $3.5 million, and provided key business updates. The company secured a direct investment led by BVF Partners L.P., raising $8.5 million, bringing total cash to $20.4 million as of May 8, 2026, expected to fund operations through Q1 2027. Significant pipeline advancements include the submission of the EB613 Phase 3 protocol to the FDA for osteoporosis and an expanded 50/50 partnership with OPKO for EB612, with an IND filing planned for late 2026. The company also announced management changes, appointing Geno J. Germano as Chairman.
Key Highlights
- Direct investment led by BVF Partners L.P. raised $8.5 million in April 2026.
- Cash and cash equivalents totaled $20.4 million as of May 8, 2026.
- Q1 2026 net loss was $3.5 million, or $0.07 per ordinary share.
- Q1 2026 R&D expenses increased to $2.3 million from $1.1 million YoY.
- EB613 Phase 3 protocol submitted to FDA for 750 postmenopausal women with osteoporosis.
- EB612 partnership with OPKO expanded, with IND filing expected in late 2026.
- Geno J. Germano appointed Chairman of the Board in February 2026.